Melanoma

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD

Metastatic Melanoma with Adil Daud, MD and Boris C. Bastian, MD, PhD

With 2 different BRAF/MEK combination regimens approved by the FDA, as well as an immunotherapy combination, treatment and sequencing decisions for metastatic BRAF-mutated melanoma can be difficult.

As I write this, the 2016 ASCO conference has just concluded in Chicago. And, as is typical with this event, the amount and level of groundbreaking research and information presented at this year's conference is nothing less than staggering in its scope, innovation, and promise.

Norman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses the significance of the ipilimumab/nivolumab findings from the CheckMate-069 trial for melanoma.

For patients with NRAS-mutant melanoma who progress following treatment with an immunotherapy agent, the MEK inhibitor binimetinib offers a promising option.

The purpose of this retrospective study is to evaluate tumor response rates and toxicity profiles of IL-2 therapy in a more contemporary cohort of patients with metastatic melanoma and a history of brain metastases.

Binimetinib, a MEK inhibitor, is seeking FDA approval in the treatment of patients with advanced NRAS-mutant metastatic melanoma.

A variety of dual immunotherapy combination regimens are currently under exploration that could build upon the success seen with the addition of the CTLA-4 inhibitor ipilimumab (Yervoy) to PD-1 blockade with nivolumab (Opdivo) for the treatment of patients with advanced melanoma.

A phase II study is exploring the oncolytic virus talimogene laherparepvec (T-VEC; Imlygic) in the neoadjuvant setting for patients with resectable melanoma.